Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirine Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2009
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Tarchalska-Kryńska, B., & Postuła , M. (2009). Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirine. Medycyna Faktów , 2(2(3), 21-23. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2661
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Van de Werf F., Bax J., Betriu A. et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 2008; 29: 2909-2945.
2. Snoep J.D., Hovens M., Eikenboom J.C.J. et al.: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am. Heart J. 2007; 154: 221-231.
3. Kim K.A., Park P.W., Hong S.J. et al.: The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 2008; 84: 236-42.
4. Simon T., Verstuyft C., Mary-Krause M. et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009; 360: 363-75.
5. Mega J.L., Close S.L., Wiviott S.D. et al.: Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009; 360: 354-62.
6. Siller-Matula J.M., Spiel A.O. et al.: Effects of pentoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009; 157: 148-52.
7. Juurlink D.N., Gomes T., Ko D.T et al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180(7).
8. Neubauer H., Mugge A.: Thienopyridines and statins: assessing a potential drug-drug interaction. Curr. Pharm. Des. 2006; 12: 1271-80.
9. Bliden K.P., DiChiara J., Lawal L. et al.: The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J. Am. Coll. Cardiol. 2008; 52: 531-533.
10. Bhatt D.L., Scheiman J., Abraham N.S. et al.: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet
therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.
2. Snoep J.D., Hovens M., Eikenboom J.C.J. et al.: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am. Heart J. 2007; 154: 221-231.
3. Kim K.A., Park P.W., Hong S.J. et al.: The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 2008; 84: 236-42.
4. Simon T., Verstuyft C., Mary-Krause M. et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009; 360: 363-75.
5. Mega J.L., Close S.L., Wiviott S.D. et al.: Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009; 360: 354-62.
6. Siller-Matula J.M., Spiel A.O. et al.: Effects of pentoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009; 157: 148-52.
7. Juurlink D.N., Gomes T., Ko D.T et al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180(7).
8. Neubauer H., Mugge A.: Thienopyridines and statins: assessing a potential drug-drug interaction. Curr. Pharm. Des. 2006; 12: 1271-80.
9. Bliden K.P., DiChiara J., Lawal L. et al.: The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J. Am. Coll. Cardiol. 2008; 52: 531-533.
10. Bhatt D.L., Scheiman J., Abraham N.S. et al.: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet
therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.